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The cellular cytoskeleton, adhesion receptors, extracellular matrix composition, and their spatial distribution are together
fundamental in a cell’s balanced mechanical sensing of its environment. We show that, in lung injury, extracellular matrix-integrin
interactions are altered and this leads to signalling alteration and mechanical missensing. The missensing, secondary to matrix
alteration and cell surface receptor alterations, leads to increased cellular stiﬀness, injury, and death. We have identified a mono-
clonal antibody against β1 integrin which caused matrix remodelling and enhancement of cell survival. The antibody acts as an
allosteric dual agonist/antagonist modulator of β1 integrin. Intriguingly, this antibody reversed both functional and structural
tissue injury in an animal model of degenerative disease in lung.
1. Introduction
Tissue regeneration comprises dediﬀerentiation of adult cells
into a stem cell state and the development of these cells into
new remodelled tissue, identical to the lost one. Tissue repair
is defined as replacement of normal tissue by fibrous tissue
and integrins are crucial in these processes.
Integrins are membrane spanning proteins facilitating
the two-way communication between the inside and outside
of a cell. Integrins have the capacity to bind a multitude of
molecules both inside and outside of the cell. The binding
of these molecules results in the transmission of information
into and out of the cell, which can influence a host of dif-
ferent cellular functions, including the cells metabolic activ-
ity.
Of the many types of integrin receptors, the β1 integrin
is by far the most ubiquitous allowing cells to detect a vast
array of stimuli ranging between toxins, protein hormones,
neurotransmitters, and macromolecules. There have been
numerous publications documenting a potential role of β1
integrin in tissue development and repair in several tissue
types (reviewed in [1]). It is clear that β1 integrin plays a
crucial role during postnatal skin development and wound
healing, with the loss of epithelial β1 integrin causing exten-
sive skin blistering and wound healing defects. More recently,
there has been active interest in the cosmeceutical develop-
ment of β1 integrin targeting formulations. One such ex-
ample is following the discovery of fucoidans from Fucus
vesiculosus and its eﬀect on skin scarring and ageing [2, 3]
which was later found to be mainly attributed to alpha2 and
β1 integrin [4].
Integrins in general, including β1 integrin, exhibit global
structural rearrangement and exposure of ligand binding
sites upon activation [5]. The overall strength of cellular ad-
hesiveness, or avidity, is governed by aﬃnity and valency
(which is in turn governed by the density of the receptor and
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its ligand on the cell surface, as well as the spatial and geo-
metric arrangement and movement) [5]. Recent evidence
has demonstrated that both aﬃnity and avidity of integrins
are strongly related to the size of the focal adhesion clusters
[6, 7]. Overall, integrins have three main possible conforma-
tions of the extracellular domain; a low aﬃnity, bent con-
formation; extended conformation with closed headpiece
representing an intermediate aﬃnity state; the ligand-bind-
ing-induced high-aﬃnity extended form, with an open head-
piece [8–10].
Altered conformation of integrins rather than expression
levels have been reported both during physiological and
pathological remodelling processes which include neurite
outgrowth, fibrosis, asthma, cancer, and wound healing
amongst many [11–14]. To successfully develop diseasemod-
ifying therapy, it should be beneficial to rescue or replenish
dying or dead cells by activating inherent repair processes
other than simply stem cell regeneration. In other words,
altering the interaction of the cells with other cells and their
abnormal surroundings to promote their survival and con-
tinued function may alleviate chronic, ongoing cell loss, a
hallmark of many progressive degenerative diseases. We hy-
pothesised that tissue repair might be achieved by rescueing
cells from death by mechanically dampening the signals cells
receive from their abnormal environment. One key cell sur-
face receptor for adhesion is β1 integrin. We considered that
conformational modulation of β1 integrin may cause alter-
ation in cytoskeletal organization and cell stiﬀness leading to
increase susceptibility to oxidative stress and death and thus
that prevention of these changes may have therapeutic bene-
fit. Here, we show how we have identified a specific β1 inte-
grin targeting modality using a monoclonal antibody, which
we have demonstrated, both protects from tissue injury and
facilitates repair. The antibody acts as an allosteric dual
agonist/antagonist modulator of β1 integrin and resulted
in increased matrix remodelling and enhancement of cell
survival.
2. Results
2.1. The Eﬀects of β1 Integrin Modulation on Elastase-Induced
Signalling. As a model of tissue remodelling in disease, we
investigated the activity of β1 integrin using an in vitromodel
of elastase-induced injury. A coculture of primary, adult
human lung fibroblasts was overlayered with NCI-H441 lung
cells, under cyclic mechanical stimulation, and subjected to
elastase treatment.
To investigate the involvement of β1 integrin activation
in elastase-induced signalling, we used three diﬀerent mon-
oclonal antibodies against β1 integrin. The first was the ad-
hesion blocking clone, JB1a, which is said to target primarily
the amino acids 82–87 comprising part of the hybrid domain
[15]. We also used the adhesion blocking clone, AIIB2, which
binds amino acid residues 207–218 within the A-domain
[16], and K20, widely reported to have no functional eﬀects
which binds the hybrid/EGF repeat region [17].
Addition of elastase to cell culture induced an increased
phosphorylation of signalling proteins known to act down-
stream of β1 integrin (Figure 1(a)). During the course of
injury, pAKT levels increased, followed by transient increases
in phospho-cJUN and phospho-JNK (Figure 1(a)). No sig-
nificant changes were detected for 12 other phosphoproteins
at the sampled time points.
When β1 integrin was bound by antibody clone JB1a in
the absence of injury, there was no significant eﬀect on down-
stream signalling. However, when JB1a was added during
elastase-induced injury, it abrogated all elastase-induced
changes in phosphorylation of signalling proteins. This eﬀect
was not seen with either AIIB2 or K20 (Figure 2(a)).
2.2. The Eﬀects of Elastase-Induced Injury on β1 Integrin Activ-
ity and Localisation. We next examined the eﬀects of elastase
on ligand-binding activity of β1 integrin using the ligand
competent specific anti-β1 integrin antibody 9EG7. Ligand
competent state can be any of the intermediate physiological
conformations or the fully activated extended conformation
[19]. Elastase caused an increase in ligand competent/active
β1 integrin expression as evident from the staining pattern
in Figure 1(b). Modulation of β1 integrin, using JB1a, abro-
gated the elastase-induced increase in ligand-competent β1
integrin (Figure 1(b)). However, the anti-β1 integrin clone
K20 potentiated the elastase-induced increase in the ligand-
competent conformation (Figure 2(b)).
The eﬀects of elastase and JB1a on the level of ligand-
competent receptor were not simply a result of change in cell
surface expression (Figure 1(c)). However, preliminarymeas-
urements showed that elastase increased the cytosolic frac-
tion-associated β1 integrin which might be attributed to
recycling or degradation. To address that we conducted a
time course analyses of β1 integrin in membrane fractions.
Elastase induced a change in β1 integrin recycling, an eﬀect
inhibited by JB1a but not K20 (Figure 3). Further evidence
of elastase-induced β1 integrin activation was the increase of
caveolin-1 phosphorylation after two hours of exposure to
elastase; changes once again inhibited by JB1a (Figure 4).
2.3. The Conformational Eﬀects of JB1a on β1 Integrin. To
further determine the pharmacological mode of action of
JB1a action, we questioned whether the eﬀect seen with JB1a
is due to its eﬀect on β1 integrin chain allostery. We first esti-
mated the location of the epitope of JB1a on the basis of the
theoretical 3-dimentional structure of β1 integrin (Figure
5(a)). We then conducted FRET studies using nonadherent
Jurkat cells. FITC-labelled LDV cyclic peptide was used to
label the head of alpha4β1 integrin, and the lipophilic dye
R18 was used to label the cell membrane. LDV-FITC acts as
a donor and R18 as an acceptor [20]. FACS was used for the
FRET acquisition and measurement. JB1a caused a confor-
mational activation when added at baseline and inhibited
the full conformational activation induced by the divalent
cation, Mn2+. The JB1a-induced change resulting in FRET
eﬃciency was indicative of an intermediate partially extend-
ed conformation when compared to Mn2+ and other known
inhibitory or activating antibodies (Figures 5(b)–5(e)).
Taking together these findings indicated that the phar-
macological mode of action of JB1a-mediated eﬀect on β1
integrin is as an allosteric dual agonist/antagonist.
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Figure 1: The eﬀects of PPE-induced injury and JB1a treatment on (a) activation of signalling downstream of beta1 integrin during mecha-
nical stretch (asterisks denote statistical significance with P < 0.05 in comparison to PPE) and (b) beta1 integrin conformational activation
indicated by increase in staining using the anti-β1 integrin antibody 9EG7 recognising the ligand competent receptor in comparison to
staining using nonconformation dependent antibody (K20).
2.4. Conformational Modulation of β1 Integrin Inhibits Elas-
tase-Induced Changes in Cell Membrane Composition. Using
mixed epithelial-mesenchymal in vitro cultures, we found
that elastase increased neutral sphingomyelinase activity
transiently; an eﬀect inhibited by β1 integrin binding by anti-
body JB1a (Figure 6(a)). No eﬀect on acid sphingomyelinase
was detected under the same conditions.
2.5. Conformational Modulation of β1 Integrin Inhibits Elas-
tase-Induced Changes in Actin Polymerisation and Cellular
Impedance. Using our in vitro culture system, we tracked
incorporation of labelled monomeric actin, and demon-
strated an increase in de novo F-actin formation during
the course of elastase-induced injury (Figures 6(b), 12,
and S1–S3 in Supplementary Material available online at
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Figure 2: The eﬀects of PPE-induced injury and targeting beta1 integrin using AIIB2 and K20 clones on (a) activation of signalling down-
stream of beta1 integrin during mechanical stretch (asterisks denotes statistical significance with P < 0.05 in comparison to PPE) and (b)
beta1 integrin conformational activation indicated by increase in staining using the anti-β1 integrin antibody 9EG7 recognising the ligand
competent receptor in comparison to staining using nonconformation dependent antibody (K20).
doi:10.1155/2012/768720). Formation of F-actin from mo-
nomeric G-actin is energy dependent, and, under ATP
depletion conditions, there is a net conversion of monomeric
G-actin to polymeric F-actin. In cocultures, elastase reduced
the levels of ATP, but this response was inhibited by JB1a
(Figure 6(c)).
To corroborate the finding on cellular mechanical prop-
erties, we investigated the eﬀect of elastase on cellular impe-
dance. There was an initial drop and recovery in impedance
after change of media consistent with responses to sudden
stretch, as reported previously [21]. JB1a inhibited the elas-
tase-induced decrease in cellular impedance (Figure 6(d)).
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Figure 3: The eﬀects of PPE-induced injury (0.6U/mL) and tar-
geting beta1 integrin using JB1a (1 ug/mL) in comparison to K20
(1 ug/mL) clone on the kinetics of beta1 integrin levels on cell mem-
brane in vitro using human lung coculture. (a) Western blot of the
cell membrane expression of β1 integrin over time. Protein extracts
were loaded at equal protein concentration (25 μg). (b) Densitomet-
ric analyses of the blot corrected using actin as an internal control.
2.6. Conformational Modulation of β1 Integrin Inhibits Elas-
tase-Induced Caspase Activation. We then investigated the
eﬀect of elastase on caspase activation and the role of β1 inte-
grin in elastase-induced cell death. Elastase induced caspase
activation after 3-hour exposure and led to detachment in-
duced apoptosis of epithelial cells (anoikis) (Figures 7(a) and
S1–S3). Modulation of β1 integrin using JB1a prevented cas-
pase activation. However, the potently inhibitory anti-β1 in-
tegrin antibody 6S6, which is also known to induce homo-
typic aggregation, induced caspase activation (Figure 7(b)).
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Figure 4: The eﬀects of PPE-induced injury (0.6U/mL) and
targeting beta1 integrin using AIIB2 (1 ug/mL) and K20 (1 ug/mL)
clones on phosphorylated caveolin-1 levels in membrane fractions.
(a) Representative blots from n = 4. Loading controlled by total
amount of protein (50 μg). (b) Densitometric analyses of the blot
corrected using actin as an internal control.
2.7. Conformational Modulation of β1 Integrin Reversed Elas-
tase-Induced Emphysema in Mice. To investigate the signifi-
cance of β1 integrin in injury in a disease setting in which
remodelling is a key component, we established a murine
model of emphysema caused by intratracheal installation of
elastase. Mice were instilled with elastase on day 1 and lung
injury ensued. At later timepoints, they were treated with the
anti-β1 integrin monoclonal antibody, JB1a which binds β1
integrin in mouse tissues [22], or vehicle, either once on day
14 (21 day group, 21 d) or on days 21 and 28 (35 day group,
35 d). In a subsequent investigation, severe emphysema was
induced and JB1a and B44 clones were instilled on days 21
and 28 before lung function assessment on day 35. Both
clones demonstrated cross-reactivity with murine β1 inte-
grin (Figure 8).
By 21 days after elastase injury, there was a marked
progressive leftward shift in the respiratory pressure-volume
curve (PV) of close-chested mice, particularly in the 35 day
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Figure 5: (a) The location of JB1a epitope as mapped by Ni and Wilkins [15] produced using polyview 3D as described in [18]
http://polyview.cchmc.org/polyview3d.html FRET analyses demonstrating. (b) the baseline conformation of beta1 integrin and following
Mn2+-induced integrin activation. The eﬀect of JB1a (c), K20 (d), and B44 (e) on integrin at baseline and on Mn2+-induced integrin
activation detected by FRET using the LDV-FITC small molecule and R18 in Jurkat cells. LDV binding is plotted as mean channel
fluorescence (MCF) versus time.
group (Figure 9(a)). JB1a, given as a single intratracheal dose
at this time point, reversed the loss of respiratory elastic recoil
induced by elastase treatment (Figure 9(b)).
In addition to the reversal of functional characteristics,
treatment with JB1a was associated by structural repair,
assessed by histology and morphometry (Figure 9(c)). In
elastase-treated lungs, apoptosis was demonstrated by the
TUNEL assay at 21 and 35 days, even in the absence of
inflammation. This was prevented by JB1a treatment (Figure
9(d)). There was no change in cellular proliferation as
assessed by immunostaining for Ki67. The eﬃcacy of β1
integrin modulation using the clone JB1a was evident even in
more severe injury when a higher dose of elastase was used.
(Figure 10).
When we tested the eﬀect of β1 integrin modulation us-
ing JB1a in comparison to the clone B44 following the same
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Figure 6: The eﬀects of PPE-induced injury (0.6U/mL) and JB1a treatment (1 ug/mL) in vitro using human lung coculture cultured on
collagen-coated surfaces. The eﬀects measured were on (a) neutral sphingomyelinase activity one on cultures subjected to mechanical stretch
of 2–10% amplitude at 1Hz (n = 3), (b) F-actin using 3D reconstruction of images of human lung coculture after injury using elastase
demonstrating the formation of F-actin (blue) and caspase 3/7 activation (red). Ganglioside GM1 for the cell membrane-green and its
inhibition by JB1a done on cells cultured on glass (n = 3), (c) ATP levels (n = 3 and each included separate measurements of cells cultured
in 8 wells in 96-well plates). (d) Cellular electrical impedance (n = 3).
protocol of the 35 day group, B44 had no significant eﬀect at
a comparable dose (Figures 11(a) and 11(b)). The clone B44
bears the closest resemblance in its conformational eﬀect to
the JB1a from our FRET results. In parallel studies, we tested
the potent inhibitory antibody, 6S6 known to induce homo-
typic aggregation. Whilst 6S6 had no eﬀect in control ani-
mals, its eﬀect on elastase-treated animals was detrimental
and worsened injury corroborating it proapoptotic eﬀect
in vitro.
3. Discussion
In this paper we have investigated the role of β1 integrin in
lung injury and repair in emphysema. We demonstrated that
β1 integrin becomes allosterically activated in epithelial-mes-
enchymal cells, with the corollary that allosteric modulation
inhibited elastase-induced injury. We further demonstrate a
potential cellular mechanism for this β1 integrin-mediated
eﬀect. In order to do so, we established an in vitro model
system which replicated features of elastase-induced emphy-
sema in vivo. We identified that allosteric modulation of β1
integrin inhibited caspase activation, F-actin aggregate for-
mation, and abnormal fluctuations in cellular ATP levels, un-
der conditions in which the total β1 expression was changed
and activation inhibited. The key finding of our investigation
was that, by direct allosteric modulation of β1 integrin with a
specific monoclonal antibody, both functional and structural
reversal of elastase-induced tissue injury was induced in vivo.
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Figure 8: JB1a and B44 immunoreactivity with beta1 integrin ver-
ification on human tissues and their cross-reactivity with beta1 in-
tegrin in mouse tissue. Images were collected using ×40 oil lens
and Zeiss LSM510 CLSM microscope with nyquist settings. The re-
sulting images were deconvolved, and three-dimensional images
were reconstructed using Huygens software (Scientific Volume Im-
aging (SVI), The Netherlands).
Our findings support the notion that cytomechanics are im-
portant determinants of cell fate and eﬀect repair.
Upon activation, integrin-linked kinase (ILK) binds to
the cytoplasmic domain of the β1 integrin subunit [23]. In
turn, ILK activates multiples signalling pathways such as pro-
tein kinase B (PKB/AKT) and inhibits glycogen synthase
kinase-3β (GSK-3β) activity aﬀecting transcription factor
binding to their DNA sequences [23–25]. We demonstrated
that elastase-induced injury activated signalling downstream
of β1 integrin and this eﬀect was modulated by targeting β1
integrin using the clone JB1a. Although JB1a is known as an
inhibitory antibody, the eﬀect on elastase-induced signalling
was specific to JB1a since targeting β1 integrin using the in-
hibitory clone AIIB2 did not have the same eﬀect nor did the
clone K20. The elastase-induced activation of β1 integrin was
corroborated by demonstrating that there was an increased
detection of ligand-competent β1 integrin which was not
caused by increased protein level but rather increased re-
cycling. By contrast, the anti-β1 integrin clone K20 induced
an increase in the ligand-competent conformation; an eﬀect
previously noted [26].
The separation of the alpha and β subunit legs is a critical
step in integrin activation to transform the bent structure to
an extended conformation, thus allowing headpiece-ligand
engagement [8]. Therefore, we questioned whether the eﬀect
seen with JB1a is due to its eﬀect on β1 integrin chain al-
lostery. Indeed, targeting amino acid sequences within the
same epitope of JB1a in the hybrid domain region using other
antibodies has been reported to stabilise the physiological
intermediate state of the receptor in a similar fashion as an
allosteric antagonist [8]. We adopted an assay method used
to detect conformational changes in integrin [20, 27] and
found that, under baseline conditions, JB1a had an activating
eﬀect whilst it acted as a conformational antagonist when β1
integrin was activated with manganese. We have examined
8 other clones and determined that the clones closest to
JB1a in its conformational eﬀect were the B44 and HUTS 21
clones; both of which bind to the second hybrid domain of β1
integrin (reviewed in [1]). Therefore, adding to the reported
eﬀects of JB1a, we have shown that it functions both as an
agonist and antagonist.
We then sought to elucidate the significance of integrin
activation in response injury. Receptor clustering is, in part,
aided by interactions with cellular proteins such as caveolins
cell membrane fluidity. The composition of cell plasma
membrane directly aﬀects β1 integrin function and mem-
brane fluidity in response to other types of injury [28, 29],
reviewed in [1]. In using in vitro mixed epithelial-mesen-
chymal cultures, we found that elastase increased neutral
sphingomyelinase activity transiently; an eﬀect inhibited by
β1 integrin binding by antibody JB1a. The association of
neutral sphingomyelinase has been shown recently in ciga-
rette smoke models of lung injury [30].
Gene disruption of caveolin-1, which is known to be in-
volved in integrin clustering and activation, results in pul-
monary fibrosis and impairment in liver regeneration after
partial hepatectomy which was reversible by treatment with
glucose [31], indicating the probable importance of energy
preservation. Interestingly, previous reports have shown
that β1 integrin-mediated adhesion regulates cholesterol-
rich membrane microdomain internalisation mediated by
phosphocaveolin-1 [32] and caveolar endocytosis can be
blocked by small interfering RNA knockdown of β1 integrin
[33]. Our finding that allosteric modulation inhibits elastase-
induced caveolin phosphorylation reinforces the idea that,
in injury, abnormal integrin activation and clustering con-
tribute to cellular damage in elastase-induced injury.
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Figure 9: The eﬀect of porcine pancreatic elastase (PPE, 0.2U/g) on respiratory function in mice and its reversal using the anti-beta1
integrin antibody JB1a (3mg/kg). (a) The eﬀect of PPE on mean respiratory pressure-volume curves in mice from the 21days (21 d) and 35
days (35 d) after instillation and its reversal by JB1a (vehicle =Veh). (b) Reversal of PPE-induced increase in the quasistatic elastance between
5 and 9 cm H2O by JB1a treatment at diﬀerent time points after injury. (c) Mean linear intercept (Lm) measurements from the 21 d and 35 d
groups. n = 5-6 in 35 d groups and n = 10 in 21 d groups. (d) TUNEL staining demonstrating the eﬀect of JB1a treatment after PPE-induced
lung injury. (c) quantification of TUNEL positive cells in lung tissue sections from 21 d and 35 d group following PPE-induced injury and
JB1a treatment (n = 5-6 per group). Asterisks denote statistical significance with ∗P < 0.05, ∗∗P < 0.005 and ∗∗∗P < 0.0005 in comparison
to vehicle.
Integrin activation can occur via outside-inside and/or
inside-outside signalling. We postulate from our results that
outside-inside β1 integrin signalling and activation are in-
duced during injury, possibly as a result of extracellular
matrix degradation (reviewed in [1]). Matrix integrity has
been shown to play a key role in various injuries including
emphysema [34] and amyloid β neurotoxicity [35]. Indeed,
unpublished data from our laboratory have shown that
β1 integrin allosteric modulation using JB1a, but not 6S6
or TS2/16, caused an increase in perlecan [36]; a change
partially sensitive to pretreatment with cycloheximide and
the nonspecific metalloproteinase (MMPs) activator amino-
phenylmercuric acetate (APMA). The changes in perlecan in
response to JB1a were accompanied by an increase in tissue
inhibitors of metalloproteinase-1 (TIMP1) initially and pro-
MMP-9 subsequently.
Integrin activation can also occur due to cellular changes
[37, 38]. Various reports highlighted the eﬀect of plasma
membrane lipid composition on β1 integrin function [29,
39, 40]. Ceramide increase during elastase-induced injury
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Figure 10: Dose-response of the eﬀects of porcine pancreatic elas-
tase (PPE, 0.2U/g and 0.3U/g) on respiratory function in mice and
its reversal using the anti-beta1 integrin antibody JB1a. The eﬀect of
PPE on mean respiratory pressure-volume curves in mice from 35
days (35 d) after instillation and its reversal by JB1a (vehicle = Veh).
has been shown to cause apoptosis [30, 41]. We have shown
that, upon the onset of elastase-induced injury, neutral
sphingomyelinase increased which may have contributed to
β1 integrin activation; an eﬀect inhibited by modulation of
β1 integrin using JB1a.
Integrin activation is associated with increased engage-
ment with the actin cytoskeleton [42, 43]. More recently,
actin polymerisation has been shown to be aﬀected in ciga-
rette smoke models [44]. We have investigated actin poly-
merisation in our in vitro system during the course of elas-
tase-induced injury and the eﬀect of β1 integrin modulation
on the process. We used live cell imaging of labelled mono-
meric actin incorporation to ascertain de novo increase in the
formation of actin aggregates since the phalloidin staining
fails to demonstrate the newly formed aggregate. We were
able to show an increase in actin aggregates during the course
of elastase-induced injury. This eﬀect was inhibited by mod-
ulation of β1 integrin.
We then investigated how elastase-induced injury im-
pacted on ATP. Under ATP depletion conditions, there is a
net conversion of monomeric G-actin to polymeric F-actin
resulting from an alteration in the ratio of ATP-G-actin and
ADP-G-actin with the resultant F-actin forming dispersed
aggregates [45]. We chose to characterise ATP dynamic
changes in vitro following elastase-induced injury. We found
not only the levels were reduced after prolonged exposure but
preceding this reduction, abnormal fluctuations were detect-
ed at the onset of exposure to elastase. These responses were
inhibited by allosteric modulation of β1 integrin.
With changes in cell membrane composition and actin
cytoskeleton, we sought to confirm if those changes have im-
pacted on cellular mechanical properties. We have shown
that cellular impedance is altered during the course of elas-
tase-induced injury and this eﬀect was inhibited by modula-
tion of β1 integrin. Although this measurement does not dis-
tinguish between eﬀects caused by changes in cellular com-
position and cell-cell interaction, when taken together with
evidence of alteration in actin polymerisation and cell mem-
brane composition, it further supports our notion. There
is strong evidence for the role of the state of the actin cyto-
skeleton on cell survival and diﬀerentiation which mainly
came from studies focused on thymosin β4. Thymosin β4
functions mainly as a sequestering protein of actin mono-
mers and promotes wound healing and cardiac repair by
aﬀecting cell survival [46].
Furthermore, we were able to show caspase activation in
both end-point assays and real time. Elastase-induced cas-
pase activation was inhibited by the modulation of β1 in-
tegrin. However, complete inhibition of β1 integrin using 6S6
clone (potent inhibitor and inducer of homotypic aggrega-
tion) has activated caspase.
Our findings support the hypothesis that cellular mecha-
nics play a key part in cell fate and therefore aﬀect repair. To
investigate this in a disease setting in which remodelling is a
key component, we established a murine model of emphy-
sema caused by intratracheal instillation of elastase. Emphy-
sema is an irreversible component of chronic obstructive
pulmonary disease, a major cause of morbidity andmortality
worldwide.
We hypothesised that, in irreversible moderately severe
emphysema, β1 integrin becomes allosterically activated,
with the corollary that only then might allosteric modulation
become therapeutically beneficial. The expression of activa-
tion epitopes of β1 integrin, hence a fully extended active
conformation, in human disease is poorly understood due
to the technical limitations. However, recently, the presence
of ligand competent β1 integrin in eosinophils from induced
sputum samples of asthmatic patients was investigated and
found to correlate with airway hyperresponsiveness [47].
Modulation of β1 integrin using JB1a reversed elastase-
induced emphysema when administered at the two diﬀerent
time points after the onset and stabilisation of emphysema. It
had no eﬀect on vehicle instilled animals. This was confirmed
by both unconscious lung function testing and structural
analyses using the mean linear intercept. We have also
previously determined that modulating β1 integrin function
allows septation to proceed in damaged lungs by altering the
pool of GATA-6 and TTF-1 expressing cells [48].
Although, the clone B44, which had the closest eﬀect
to JB1a-induced conformational eﬀect, showed some eﬀect
on elastase-induced lung function abnormalities, it has de-
creased lung compliance in normal animals. We have not yet
determined whether the clone B44 has induced fibrosis or
alteration in airway responsiveness to account for the ob-
served functional eﬀects.
Thus targeting β1 integrin with JB1a induced previously
unseen disease-modifying eﬀects. The key event, evident
from our research, is the synergistic alteration of cell surface
receptor distribution leading to alteration in receptor activity
state and changes in the cell membrane composition. This
eﬀect makes cells more adaptable to their altered mechanical
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Figure 11: The eﬀects of porcine pancreatic elastase (PPE, 0.3U/g) on respiratory function in mice and its reversal using the anti-beta1
integrin antibody JB1a (3mg/kg) in comparison to the anti-beta1 integrin clone B44 (3mg/kg). (a) The eﬀect of PPE on mean respiratory
pressure-volume curves in mice from 35 days (35 d) after instillation and its reversal by JB1a and not B44. (b) Reversal of PPE-induced
increase in the quasi-static elastance between 5 and 9 cm H2O by JB1a treatment (n = 6–10). Asterisks denote statistical significance with
∗P < 0.05, ∗∗P < 0.005, and ∗∗∗P < 0.0005 in comparison to vehicle.
Figure 12: Selected frames from time lapse videos of epithelial-mesenchymal cultures during stretch (compressed videos) demonstrating
the formation of F-actin (blue) and caspase 3/7 activation (red) in reponse to elastase (PPE, 0.6U/mL) and its inhibition by JB1a done on
cells cultured on glass. Sytox green was used for cell tracking. (a) control, (b) PPE (0.6U/mL), and (c) PPE + JB1a (1 ug/mL).
environment, thereby reducing the tendency of injury to
cause increased cell stiﬀness, loss of energy, and ultimately
death.
4. Material and Methods
4.1. Signalling. Adult human lung fibroblasts (ATCC, CCD-
8Lu) were seeded onto collagen-I-coated BioFlex 6-well
plates at 0.5 × 106/well. The following day, NCI-H441 cells
were seeded on top of the fibroblasts at the same density.
Cells were starved with media containing 0.1% FCS. The
plates were subjected to stretching at 2–10% sinusoidal
stretch at 1Hz for 2, 4, or 6 hours. PPE was added at
0.3U/mL alone or in combination with JB1a (1 μg/mL, gift
from John Wilkins, Manitoba), AIIB2 (1 μg/mL, Develop-
mental Studies Hybridoma Bank of University of Iowa), or
12 Advances in Pharmacological Sciences
K20 (1 μg/mL, Santa Cruz). At the end of the stretch, the
media was aspirated and protein extracted from the cell layer
using Bio-Plex cell lysis kit (Bio-Rad). The protein concen-
tration in the lysates was measured using BCA method.
Lysates were analysed for phosphoproteins (50 μg/sample)
using Bio-Plex Phospho 15-Plex assay kit (Bio-Rad) for Akt,
c-Jun, CREB, ERK1/2, GSK3, histone H3, HSP27, IκB, IRS-1,
JNK, MEK1, P38 MAPK, Src, and STAT3 and 6. Measure-
ments were according to manufacturer instructions.
4.2. β1 Integrin Imaging. Adult human lung fibroblasts
(CCD-8Lu, ATCC, Rockville, MD) were seeded onto col-
lagen-I-coated glass coverslips. The following day, NCI-H441
(ATCC, Rockville, MD) was seeded on top of the fibroblasts
at the same density. Cells were starved with media containing
0.1% FCS. The plates were subjected PPE at 0.3U/mL alone
or in combination with JB1a (1 μg/mL) or K20 (1 μg/mL) for
1 and 3 hours. The cells were then fixed using ice-cold 4%
paraformaldehyde. The cells were blocked using SuperBlock
(Pierce) and double immunostained using antibodies against
ligand competent β1 integrin (9EG7, BD Biosciences) and
JB1a followed by Alexa 488 anti-rat and Alexa 555-anti-
mouse, respectively, and nuclear staining with TO-PRO3.
Images were acquired using Zeiss LSM 510 using×40 oil lens
and raw images presented using LSM image browser.
4.3. Fluorescence Resonance Energy Transfer (FRET). The
human leukemia Jurkat (clone E6-1) cell line was purchased
from ATCC (Rockville, MD). Octadecyl rhodamine B chlo-
ride (R18) was from molecular probes. The FITC-conjugat-
ed analog of α4 specific peptide 4-((n′-2-methylphenyl)urei-
do)-phenylacetyl-L-leucyl-L-aspartyl-L-valyl-L-prolyl-L-al-
anyl-L-alanyl-L-lysine (LDV-FITC) was synthesized at Com-
monwealth Biotechnologies (Richmond, VA).
Cell- and bead-based fluorescence measurements were
performed using BD LSRFortessa. The detailed analysis of
LDV-FITC binding was described previously [20]. Cells were
treated with a range of concentrations of the fluorescent
ligand (typically 0–12 nM) in the presence of divalent cations
(1mM Mn2+), eventually choosing 4 nM for experiments.
Similar studies were done for R18 and 10 um concentra-
tion achieved saturable binding. All experiments were per-
formed in HEPES buﬀer (110mMNaCl, 10mMKCI, 10mM
glucose, 1mM MgCl2, and 30mM HEPES, pH 7.4) con-
taining 0.1% FCA. Jurkat cells were used at a density of
1 × 106 cells/mL. Kinetic analysis was done as described
previously [20]. Briefly, cells were preincubated in HEPES
buﬀer with or without divalent cations for 10min at 37◦C.
Samples were analyzed for 30 s to establish a baseline, then
the fluorescent ligand LDV-FITC was added and FACS ad.
Additional measurements were carried out in the presence of
anti-β1 integrin antibodies at 1–10 μg/mL. studies were done
where the antibody was added 1 minute before the com-
mencement of the measurements or 30 seconds after the ad-
dition of LDV-FITC without any diﬀerence observed. Data
were acquired up 600 seconds to a total of 200,000 events.
The data were converted to mean channel fluorescence over
time using FlowJo software (Tree Star, Inc., Oregon, USA).
4.4. Cell Fractionation
4.4.1. β1 Integrin. Adult human lung fibroblasts (CCD-
8Lu) were seeded onto collagen-I-coated culture dishes. The
following day, NCI-H441 cells were seeded on top of the
fibroblasts at the same density. Cells were starved with media
containing 0.1% FCS. The plates were subjected PPE at
0.3U/mL alone or in combination with JB1a (1 μg/mL) or
K20 (1 μg/mL) for 1 and 3 hours. At the end of the ex-
periment, media was aspirated and cell layer extracted using
MEM-PER protein extraction kit (Pierce), protein assayed in
the membrane fraction using the BCA methods, and 50 μg
separated onto 10% SDS-PAGE, transferred onto Hybond-
ECL (GE Healthcare). All membranes were stained with
Ponceau S (Sigma) to assess the quality of the transfer and
loading and probed for β1 integrin (JB1a) followed by HRP-
labelled secondary antibody and developed using ECL-Plus
(GE Healthcare) and exposed to Hyperfilm ECL (GE Health-
care). Densitometric analyses was carried out using Image J
(NIH).
4.4.2. Caveolin. In an additional set of experiments, cells
were cultured as described onto collagen-I-coated Bioflex
plates and subjected to stretch at 2–10% for 10, 30 minutes,
1 or 3 hours. PPE was added at 0.3U/mL alone or in com-
bination with PPE was added at 0.3U/mL alone or in com-
bination with JB1a (1 μg/mL), AIIB2 (1 μg/mL), or K20
(1 μg/mL). At the end of the stretch, the media was aspirated,
and protein extracted from the cell layer was fractionated
using the compartmental protein extraction kit (CNMCS,
Biochain). Protein content was measured using the BCA
methods. Lysates were separated onto 10% SDS-PAGE using
Biorad’s Mini Protean 3 Dodeca electrophoresis cell which
allows running 12 gels simultaneously to ensure validity for
densitometric analyses. The gels were transferred onto ECL-
hybond ECL. All membranes were stained with Ponceau S
(Sigma) to assess the quality of the transfer and loading. ECL
membranes were probed for β1 integrin using JB1a (gener-
ous gift from JohnWilkins, Manitoba) and mouse actin anti-
body (NH3, Abcam), or caveolin (rabbit anti-human, BD
Biosciences) and phosphocaveolin 1 (BD Biosciences). Sec-
ondary detection was done using 680 nm and 800 nm flu-
orescent antibodies (LiCor), and images of the blots were
acquired using LiCor system. Densitometric analyses was
carried out using ImageJ (NIH).
4.4.3. Sphingomyelinase Activity. Adult human lung fibrob-
lasts (CCD-8Lu) were seeded onto collagen-I-coated BioFlex
6 well plates at 0.5 × 106/well. The following day, NCI-
H441 cells were seeded on top of the fibroblasts at the same
density. Cells were starved with media containing 0.1% FCS.
The plates were subjected to stretching at 2–10% sinusoidal
stretch at 1Hz for 2, 4, or 6 hours. PPE was added at
0.3U/mL alone or in combination with JB1a (1 μg/mL). At
the end of the stretch, the media was aspirated, snap frozen
in liquid nitrogen, and lyophilised and enzyme activities
assayed using Amplex red sphingomyelinase assay kit (Invit-
rogen) according to the manufacturers’ instructions.
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4.4.4. Time-Lapse Studies. Cells were cultured as described
in methods at 50,000 cell/membrane onto collagen I Bioflex
membranes using silicone gaskets of 10mm diameter. Cells
were starved with media containing 0.1% FCS and Syto 16
(Molecular Probes). The media was removed, and Alexa-
Fluor 647 labelled G-actin (100 μg/membrane) from rabbit
was loaded using Influx (Molecular Probes). The cells were
loaded with PhiPhiLux-G2D2 for visualisation of caspase ac-
tivation (OncoImmune). The membrane was then mounted
onto the StageFlexer (FlexCell), placed on the stage of an
upright Leica-TCS-NT confocal microscope system (Leica
Microsystems GmbH, Heidelberg, Germany), and subjected
to 2–10% cyclic stretch at 1Hz for up to 6 hours. Images
were collected simultaneously from 3 channels at 1-minute
intervals, using the×10 lens. The resulting time-lapsemovies
were collated and analysed with Imaris software (Bitplane
AG, Switzerland). At various time points during the study,
the membrane was held static while serial optical sections
were acquired the three fluorescent channels supplemented
by the collection of the brightfield channel image.
4.4.5. Three-Dimensional Confocal Microscopy. NCI-H441
cells and human lung fibroblasts were cultured as described
above onto collagen-I-coated glass coverslips at 20,000 cells
within an area of 5mm in diameter. The media was removed
and Alexa-Fluor 647 labelled G-actin (30 μg/coverslip) from
rabbit was loaded using Influx (Molecular Probes). The cells
were loaded with PhiPhiLux-G2D2 for visualisation of cas-
pase activation (OncoImmune) and FL-ganglioside 1 (GM1,
Molecular probes) to visualise the plasmamembrane. Images
were collected through 4 separate channels (GM1: λ = 488,
caspase λ = 568, actin: λ = 647 and brightfield) using x63
water lens and Zeiss LSM510 CLSM microscope. The result-
ing images were analysed with Imaris software (Bitplane AG,
Switzerland). Three-dimensional images were reconstructed.
4.4.6. ATP Measurments. In a separate set of experiments
lung fibroblasts and epithelial cells were seeded onto 96
multi-well plates as described above. The cells were starved
in media containing 0.1% FCS then in DMEM-glucose-free
with 0.1% FCS for 45 minutes before treating with (i) PPE at
0.3U/mL alone or (ii) PPE preceded by JB1a (1 μg/mL). At
the end of the experiment, ATP levels were measured using a
bioluminescent ATP kit (Perkin Elmer).
4.4.7. Electrical Impedance. ECIS monitors the impedance of
small 250-micrometer diameter electrodes used as substrates
for cell growth. When cells grow on the electrode, they
impede current flow. Cells were layered as described before
onto slides (8W10E, Applied Biophysics) which contain 8
wells each containing ten circular 250 μm diameter active
electrodes connected in parallel on a common gold pad. PPE
was added at 0.3U/mL alone or in combination with JB1a
(1 μg/mL). Impedance was monitored using ECIS controller
model 1600 (Applied Biophysics).
4.5. Caspase Activation Measurements in Human Mesenchy-
mal and Epithelial Cell Coculture. Adult human lung fibrob-
lasts (CCD-8Lu) were seeded onto collagen-I-coated BioFlex
6-well plates at 0.5 × 106/well. The following day, NCI-H441
cells were seeded on top of the fibroblasts at the same density.
Cells were starved with media containing 0.1% FCS. The
plates were subjected to stretching at 0–5%, 0–10%, or 2–
10% sinusoidal stretch at 1Hz for 6 hours. Control plates on
plastic or bioflex plates without stretch were also included.
PPE was added at 0.3U/mL alone or in combination with
JB1a (1 μg/mL), 6S6 (1mg/mL), or ZVAD-fmk at 10 μM. At
the end of exposure period which was 1, 3, and 6 hours,
the media was aspirated and caspase 3 activity assayed using
Caspase-Glo 3/7 (Promega) according to the manufacturers’
instructions.
4.6. Cross-Reactivity of β1 Integrin Antibodies. Human and
murine neuronal cells were fixed in formaldehyde. The cells
were blocked using SuperBlock (Pierce) and immunostained
using antibodies against β1 integrin (JB1a and B44, gift from
John Wilkins, Manitoba) followed by Alexa 647 anti-mouse
(Molecular Probes) and nuclear staining with 7-AAD (Mo-
lecular Probes). Image z stacks were acquired using Zeiss
LSM 510 with Nyquist calculator settings (http://www.svi.nl/
NyquistCalculator) using Plan-Neofluar 40x/1.30 Oil DIC
lens and raw images deconuolved and presented in 3d using
Huygens software (Scientific Volume Imaging SVI, The
Netherlands).
4.7. PPE-Induced Air Space Enlargement Model in Mice. Fe-
male C57/BL6 mice (6–8 weeks old) were instilled intratra-
cheally with porcine pancreatic elastase (Roche) as detailed
before [49] at 0.2U/g. All procedures were approved by the
Ethical Review Committee of the University of Edinburgh.
The procedures were carried out under a project licence
number PPL60/3984 issued by the Home Oﬃce under the
UK Animals (Scientific Procedures) Act 1996. At day 14 (21 d
group) or 21 and 28 days (35 d group), mice were treated in-
tratracheally with the anti-integrin antibody JB1a at 3mg/kg
in sterile PBS. The dose chosen is equivalent to the dose of
clinically used antibodies against α4β1 integrin [50]. Control
group was instilled initially with PBS with either JB1a or B44
at day 14 (21 d) or at days 21, and 28 (35 d). Additional vehi-
cle control groups were instilled with PBS at days 1 and 14
(21 d) or days 1, 21 and 28 (35 d). We have carried out stud-
ies where control groups were instilled with an isotype con-
trol (MOPC21, Sigma-Aldrich) and no eﬀect was seen. For
the group treated at day 14, the animals were terminated
at day 21 (21 d), and, for the group treated on days 21 and
28, the animals were terminated on day 35 (35 d) as follows.
The animals were anaesthetised using sodium pentobar-
bitone (45mg/kg), paralysed using pancuronium bromide
(0.8mg/kg), and tracheostomised and ventilated using a
small animal ventilator (Flexivent, SCIREQ, Montreal) at
8mL/kg and a rate of 150 breaths/minute and positive end
expiratory pressures (PEEP) of 3 cmH2O.
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The pressure-volume curve was obtained during infla-
tion and deflation in a stepwise manner by applying volume
perturbation incrementally during 16 seconds. The pressure
signal was recorded and the pressure-volume (P-V) curve
calculated from the plateau of each step. The constant K was
obtained using the Salazar-Knowles equation and reflects the
curvature of the upper portion of the deflation P-V curve.
Quasistatic elastance reflects the static elastic recoil pressure
of the lungs at a given lung volume. It was obtained by cal-
culating the slope of the linear part of P-V curve.
In an additional study, female C57/BL6 mice (6–8 weeks
old) were instilled intratracheally with 0.3U/g porcine pan-
creatic elastase (Elastin products) as detailed above. At days
21 and 28, mice were treated intratracheally with either the
anti-integrin antibody JB1a or B44 at 3mg/kg in sterile PBS.
Control group was instilled initially with PBS with either
JB1a or B44 at days 21 and 28. An additional vehicle control
group was instilled with PBS at days 1, 21, and 28. Lung func-
tion was assessed as described above.
4.8. Histochemistry. After the measurements, the animals
were sacrificed and lungs were removed and formalin-fixed at
a pressure of 25 cm H2O, paraﬃn-embedded, and sectioned
at 4 μm thickness. Sagittal sections were used from each ani-
mal for histological and immunohistochemical assessment of
damage and morphometric analysis (mean linear intercept,
Lm). Images from 10 fields per section were digitised using
Image-Pro plus (version 5.1) and micropublisher 3.3 RTV
camera connected to a Zeiss Axioskope with 10x objective.
The field size was 0.83 μm × 0.63 μm. Mean linear intercept
was calculated from each field (horizontal and vertical) by
dividing the length of the line by the number of alveolar
intercepts.
4.9. Apoptosis Measurement. Terminal deoxyribonucleotidyl
transferase- (TdT-) mediated dUTP Nick End Labelling
(TUNEL) was assessed in sections using the Red ApopTagTM
Kit (Chemicon). Data for the quantification of positively
stained apoptotic nuclei was acquired using the ×40 oil
objective of a Zeiss 510 Axiovert confocal microscope system
(Carl Zeiss Ltd,Welwyn Gardens City, Herts, UK). The stage-
tiling utility was employed for the collection of 4 × 4 tiled
images, equivalent to a total area of 0.921mm × 0.921mm,
imaged from a lung section of∼8mm× 8mm (two tiles each
from right and left lobes). Images of mainly alveolar tissue
were constructed. The images were then converted to 8-bits
grey scale, and Image J was used to count total number of
cells. TUNEL positive cells were counted manually.
4.10. Statistical Analyses. All data were analysed using SPSS
for windows. Data were analysed using the general linear
model and multivariate ANOVA with post hoc t-test.
Disclosure
R. AlJamal-Naylor and D. Harrison are the inventors for
the intellectual property detailing the therapeutic eﬀects
of the modulation of β1 integrin function owned by R.
AlJamal-Naylor and Robert J. Naylor (WO2005037313 (17th
October 2003) and WO2008104808 (27th February 2007)).
The inventors are cofounders and shareholders of AVIPERO
Ltd which is developing anti-β1 integrin humanised leads for
Parkinson’s disease, emphysema, and arthritis (http://www
.avipero.com/). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of
the paper.
Authors’ Contributions
R. AlJamal-Naylor and D. Harrison contributed to the intel-
lectual property, scientific input, planning and carrying out
the experiments, and paper preparation. L. Wilson partici-
pated in the confocal imaging and time lapse experiments
in the investigation of mechanisms of injury and repair. B.
Harrison carried out the preliminary β1 integrin clustering
(immunofluorescence) and fractionation experiments. S.
McIntyre performed the ATP experiments. F. Rossi contrib-
uted to flow cytometry in the FRET studies. M. Marsden
provided technical assistance in the pilot in vivo studies.
Acknowledgments
The authors also wish to thank Robert J. Naylor for the sci-
entific and editorial guidance and James G. Martin for his
valuable scientific advice. This work was supported in part by
the Chief Scientist Oﬃce, Scottish Government. All work was
funded by the Chief Scientific Oﬃce (Scotland) under Grants
CZB4/129 and CZB4/602 in addition to endowment funding
from the Division of Pathology of Edinburgh University.
References
[1] R. Al-Jamal and D. J. Harrison, “Beta1 integrin in tissue re-
modelling and repair: from phenomena to concepts,” Pharma-
cology and Therapeutics, vol. 120, no. 2, pp. 81–101, 2008.
[2] T. Fujimura, Y. Shibuya, S. Moriwaki et al., “Fucoidan is the
active component of Fucus vesiculosus that promotes con-
traction of fibroblast-populated collagen gels,” Biological and
Pharmaceutical Bulletin, vol. 23, no. 10, pp. 1180–1184, 2000.
[3] T. Fujimura, K. Tsukahara, S. Moriwaki, T. Kitahara, and Y.
Takema, “Eﬀects of natural product extracts on contraction
and mechanical properties of fibroblast populated collagen
gel,” Biological and Pharmaceutical Bulletin, vol. 23, no. 3, pp.
291–297, 2000.
[4] T. Fujimura, S. Moriwaki, G. Imokawa, and Y. Takema, “Cru-
cial role of fibroblast integrins α2 and β1 in maintaining the
structural and mechanical properties of the skin,” Journal of
Dermatological Science, vol. 45, no. 1, pp. 45–53, 2007.
[5] M. Shimaoka and T. A. Springer, “Therapeutic antagonists
and conformational regulation of integrin function,” Nature
Reviews Drug Discovery, vol. 2, no. 9, pp. 703–716, 2003.
[6] J. C. Friedland, M. H. Lee, and D. Boettiger, “Mechanically
activated integrin switch controls α5β1 function,” Science, vol.
323, no. 5914, pp. 642–644, 2009.
[7] M. Kato and M. Mrksich, “Using model substrates to study
the dependence of focal adhesion formation on the aﬃnity of
integrin-ligand complexes,” Biochemistry, vol. 43, no. 10, pp.
2699–2707, 2004.
Advances in Pharmacological Sciences 15
[8] B. H. Luo, K. Strokovich, T. Walz, T. A. Springer, and J. Takagi,
“Allosteric β1 integrin antibodies that stabilize the low aﬃnity
state by preventing the swing-out of the hybrid domain,” Jour-
nal of Biological Chemistry, vol. 279, no. 26, pp. 27466–27471,
2004.
[9] M. Shimaoka, J. Takagi, and T. A. Springer, “Conformational
regulation of integrin structure and function,” Annual Review
of Biophysics and Biomolecular Structure, vol. 31, pp. 485–516,
2002.
[10] J. Takagi, B. M. Petre, T. Walz, and T. A. Springer, “Global con-
formational earrangements in integrin extracellular domains
in outside-in and inside-out signaling,” Cell, vol. 110, no. 5,
pp. 599–611, 2002.
[11] H. Xia, D. Diebold, R. Nho et al., “Pathological integrin sig-
naling enhances proliferation of primary lung fibroblasts from
patients with idiopathic pulmonary fibrosis,” Journal of Exper-
imental Medicine, vol. 205, no. 7, pp. 1659–1672, 2008.
[12] N. Koyama, J. Seki, S. Vergel et al., “Regulation and function of
an activation-dependent epitope of the β1 integrins in vascular
cells after balloon injury in baboon arteries and in vitro,”
American Journal of Pathology, vol. 148, no. 3, pp. 749–761,
1996.
[13] M. W. Johansson, S. R. Barthel, C. A. Swenson et al., “Eosino-
phil β1 integrin activation state correlates with asthma activity
in a blind study of inhaled corticosteroid withdrawal,” Journal
of Allergy and Clinical Immunology, vol. 117, no. 6, pp. 1502–
1504, 2006.
[14] S. Wright, N. L. Malinin, K. A. Powell, T. Yednock, R. E. Rydel,
and I. Griswold-Prenner, “α2β1 and αVβ1 integrin signaling
pathways mediate amyloid-β-induced neurotoxicity,” Neuro-
biology of Aging, vol. 28, no. 2, pp. 226–237, 2007.
[15] H. Ni and J. A. Wilkins, “Localisation of a novel adhesion
blocking epitope on the human β1 integrin chain,” Cell Adhe-
sion and Communication, vol. 5, no. 4, pp. 257–271, 1998.
[16] D. L. Brown, D. R. Phillips, C. H. Damsky, and I. F. Charo,
“Synthesis and expression of the fibroblast fibronectin recep-
tor in humanmonocytes,” Journal of Clinical Investigation, vol.
84, no. 1, pp. 366–370, 1989.
[17] M. Ticchioni, C. Aussel, J. P. Breittmayer, S. Manie, C. Pelassy,
and A. Bernard, “Suppressive eﬀect of T cell proliferation via
the CD29 molecule: the CD29 mAb 1 “K20” decreases dia-
cylglycerol and phosphatidic acid levels in activated T cells,”
Journal of Immunology, vol. 151, no. 1, pp. 119–127, 1993.
[18] A. A. Porollo, R. Adamczak, and J. Meller, “POLYVIEW: a flex-
ible visualization tool for structural and functional annota-
tions of proteins,” Bioinformatics, vol. 20, no. 15, pp. 2460–
2462, 2004.
[19] A. Chigaev, A. Waller, O. Amit, L. Halip, C. G. Bologa, and
L. A. Sklar, “Real-time analysis of conformation-sensitive anti-
body binding provides new insights into integrin conforma-
tional regulation,” Journal of Biological Chemistry, vol. 284, no.
21, pp. 14337–14346, 2009.
[20] A. Chigaev, T. Buranda, D. C. Dwyer, E. R. Prossnitz, and L. A.
Sklar, “FRET detection of cellular α4-integrin conformational
activation,” Biophysical Journal, vol. 85, no. 6, pp. 3951–3962,
2003.
[21] X. Trepat, L. Deng, S. S. An et al., “Universal physical responses
to stretch in the living cell,”Nature, vol. 447, no. 7144, pp. 592–
595, 2007.
[22] U. Cavallaro, J. Niedermeyer, M. Fuxa, and G. Christofori, “N-
CAM modulates tumour-cell adhesion to matrix by inducing
FGF-receptor signalling,” Nature Cell Biology, vol. 3, no. 7, pp.
650–657, 2001.
[23] G. E. Hannigan, C. Leung-Hagesteijn, L. Fitz-Gibbon et
al., “Regulation of cell adhesion and anchorage-dependent
growth by a new β1-integrin-linked protein kinase,” Nature,
vol. 379, no. 6560, pp. 91–96, 1996.
[24] M. D’Amico, J. Hulit, D. F. Amanatullah et al., “The in-
tegrated-linked kinase regulates the cyclin D1 gene through
glycogen synthase kinase 3β and cAMP-responsive element-
binding protein-dependent pathways,” Journal of Biological
Chemistry, vol. 275, no. 42, pp. 32649–32657, 2000.
[25] M. Delcommenne, C. Tan, V. Gray, L. Rue, J. Woodgett, and
S. Dedhar, “Phosphoinositide-3-OH kinase-dependent regu-
lation of glycogen synthase kinase 3 and protein kinase B/AKT
by the integrin-linked kinase,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 95, no.
19, pp. 11211–11216, 1998.
[26] Y. Shikata, K. Shikata, M. Matsuda et al., “Integrins mediate
the inhibitory eﬀect of focal adhesion on angiotensin II-in-
duced p44/42 mitogen-activated protein (MAP) kinase activ-
ity in human mesangial cells,” Biochemical and Biophysical Re-
search Communications, vol. 261, no. 3, pp. 820–823, 1999.
[27] A. Chigaev, A. M. Blenc, J. V. Braaten et al., “Real time analysis
of the aﬃnity regulation of α 4-integrin: the physiologically
activated receptor is intermediate in aﬃnity between resting
andMn2+ or antibody activation,” Journal of Biological Chem-
istry, vol. 276, no. 52, pp. 48670–48678, 2001.
[28] R. Barsacchi, C. Perrotta, P. Sestili, O. Cantoni, S. Moncada,
and E. Clementi, “Cyclic GMP-dependent inhibition of acid
sphingomyelinase by nitric oxide: an early step in protection
against apoptosis,” Cell Death and Diﬀerentiation, vol. 9, no.
11, pp. 1248–1255, 2002.
[29] D. K. Sharma, J. C. Brown, Z. Cheng, E. L. Holicky, D. L.
Marks, and R. E. Pagano, “The glycosphingolipid, lactosyl-
ceramide, regulates β1- integrin clustering and endocytosis,”
Cancer Research, vol. 65, no. 18, pp. 8233–8241, 2005.
[30] S. Filosto, S. Castillo, A. Danielson et al., “Neutral sphingomy-
elinase 2: a novel target in cigarette smoke-induced apopto-
sis and lung injury,” American Journal of Respiratory Cell and
Molecular Biology, vol. 44, no. 3, pp. 350–360, 2011.
[31] M. A. Ferna`ndez, C. Albor, M. Ingelmo-Torres et al., “Caveo-
lin-1 is essential for liver regeneration,” Science, vol. 313, no.
5793, pp. 1628–1632, 2006.
[32] M. A. del Pozo, N. Balasubramanian, N. B. Alderson et al.,
“Phospho-caveolin-1 mediates integrin-regulated membrane
domain internalization,” Nature Cell Biology, vol. 7, no. 9, pp.
901–908, 2005.
[33] R. D. Singh, E. L. Holicky, Z. J. Cheng et al., “Inhibition of
caveolar uptake, SV40 infection, and β1-integrin signaling by
a nonnatural glycosphingolipid stereoisomer,” Journal of Cell
Biology, vol. 176, no. 7, pp. 895–901, 2007.
[34] A. M. Houghton, P. A. Quintero, D. L. Perkins et al., “Elastin
fragments drive disease progression in a murine model of
emphysema,” Journal of Clinical Investigation, vol. 116, no. 3,
pp. 753–759, 2006.
[35] S. Wright, C. Parham, B. Lee et al., “Perlecan domain V in-
hibits α2 integrin-mediated amyloid-β neurotoxicity,” Neuro-
biology of Aging. In press.
[36] R. Al-Jamal and D. G. Harrison, “Tissue repair,”
WO2005037313, 2003, http://v3.espacenet.com/publication
Details/biblio?DB=EPODOC&adjacent=true&locale=en GB&
FT=D&date=20050428&CC=WO&NR=2005037313A2&KC=
A2.
[37] R. O. Hynes, “Integrins: bidirectional, allosteric signaling ma-
chines,” Cell, vol. 110, no. 6, pp. 673–687, 2002.
16 Advances in Pharmacological Sciences
[38] S. J. Shattil, C. Kim, and M. H. Ginsberg, “The final steps of
integrin activation: the end game,” Nature Reviews Molecular
Cell Biology, vol. 11, no. 4, pp. 288–300, 2010.
[39] R. Pankov, T. Markovska, R. Hazarosova, P. Antonov, L. Ivan-
ova, and A. Momchilova, “Cholesterol distribution in plasma
membranes of β1 integrin-expressing and β1 integrin-defi-
cient fibroblasts,” Archives of Biochemistry and Biophysics, vol.
442, no. 2, pp. 160–168, 2005.
[40] G. Pande, “The role of membrane lipids in regulation of inte-
grin functions,” Current Opinion in Cell Biology, vol. 12, no. 5,
pp. 569–574, 2000.
[41] I. Petrache, V. Natarajan, L. Zhen et al., “Ceramide upregu-
lation causes pulmonary cell apoptosis and emphysema-like
disease in mice,” Nature Medicine, vol. 11, no. 5, pp. 491–498,
2005.
[42] B. Butler, C. Gao, A. T. Mersich, and S. D. Blystone, “Purified
integrin adhesion complexes exhibit actin-polymerization ac-
tivity,” Current Biology, vol. 16, no. 3, pp. 242–251, 2006.
[43] J. D. Whittard and S. K. Akiyama, “Activation of β1 integrins
induces cell-cell adhesion,” Experimental Cell Research, vol.
263, no. 1, pp. 65–76, 2001.
[44] N. Minematsu, A. Blumental-Perry, and S. D. Shapiro, “Ciga-
rette smoke inhibits engulfment of apoptotic cells by macro-
phages through inhibition of actin rearrangement,” American
Journal of Respiratory Cell and Molecular Biology, vol. 44, no.
4, pp. 474–482, 2011.
[45] J. L. Daniel, I. R. Molish, L. Robkin, and H. Holmsen, “Nu-
cleotide exchange between cytosolic ATP and F-actin-bound
ADP may be a major energy-utilizing process in unstimulated
platelets,” European Journal of Biochemistry, vol. 156, no. 3, pp.
677–684, 1986.
[46] I. Bock-Marquette, A. Saxena, M. D. White, J. M. DiMaio, and
D. Srivastava, “Thymosin β4 activates integrin-linked kinase
and promotes cardiac cell migration, survival and cardiac re-
pair,” Nature, vol. 432, no. 7016, pp. 466–472, 2004.
[47] M. W. Johansson, S. R. Barthel, C. A. Swenson et al., “Eosino-
phil β1 integrin activation state correlates with asthma activity
in a blind study of inhaled corticosteroid withdrawal,” Journal
of Allergy and Clinical Immunology, vol. 117, no. 6, pp. 1502–
1504, 2006.
[48] R. Al-Jamal and D. J. Harrison, “Compounds and methods for
the modulation of integrin function to mediate tissue repair,”
WO2008104808, 2007, http://v3.espacenet.com/publication
Details/biblio?DB=EPODOC&adjacent=true&locale=en GB
&FT=D&date=20080904&CC=WO&NR=2008104808A2&KC
=A2.
[49] E. C. Lucey, R. H. Goldstein, R. Breuer, B. N. Rexer, D. E. Ong,
and G. L. Snider, “Retinoic acid does not aﬀect alveolar sep-
tation in adult FVB mice with elastase-induced emphysema,”
Respiration, vol. 70, no. 2, pp. 200–205, 2003.
[50] D. H. Miller, O. A. Khan, W. A. Sheremata et al., “A controlled
trial of natalizumab for relapsing multiple sclerosis,” New
England Journal of Medicine, vol. 348, no. 1, pp. 15–23, 2003.
